REPCF Stock - RepliCel Life Sciences Inc.
Unlock GoAI Insights for REPCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $353,736 | $353,735 | $353,735 | $353,735 | $353,735 |
| Gross Profit | $353,736 | $352,264 | $353,735 | $353,735 | $353,735 |
| Gross Margin | 100.0% | 99.6% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-360,000 | $-1,386,000 | $-1,393,000 | $-2,298,000 | $-1,328,000 |
| Net Income | $-97,291 | $-312,000 | $-743,000 | $-4,073,000 | $-1,580,285 |
| Net Margin | -27.5% | -88.2% | -210.0% | -1151.4% | -446.7% |
| EPS | $-0.00 | $-0.01 | $-0.02 | $-0.13 | $-0.06 |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
REPCFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 4, 2025 | — | $-0.00 | — | — |
Q2 2025 | May 19, 2025 | — | $0.01 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-0.08 | — | — |
Q4 2024 | Nov 26, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 6, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 1, 2024 | — | $0.02 | — | — |
Q4 2023 | Nov 28, 2023 | — | $-0.01 | — | — |
Q3 2023 | Sep 22, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 30, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 19, 2023 | — | $0.04 | — | — |
Q4 2022 | Nov 29, 2022 | — | $-0.02 | — | — |
Q3 2022 | Sep 6, 2022 | — | $-0.03 | — | — |
Q2 2022 | Jun 28, 2022 | — | $-0.02 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.02 | — | — |
Q4 2021 | Nov 30, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 1, 2021 | — | $-0.04 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.01 | — | — |
Q4 2020 | Nov 30, 2020 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about REPCF
What is REPCF's current stock price?
What is the analyst price target for REPCF?
What sector is RepliCel Life Sciences Inc. in?
What is REPCF's market cap?
Does REPCF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to REPCF for comparison